Lilly and Novast to expand manufacturing facility in Nantong, China

6 March 2014

US pharma major Eli Lilly (NYSE: LLY) and China-based generic and specialty pharmaceutical company Novast Laboratories have commenced the expansion of manufacturing and development facility capacities in Nantong, Jiangsu, China.

The expansion is a result of Lilly's strategic partnership signed in 2012 with Novast to create a platform of Lilly-branded generic medicines (The Pharma Letter June 13, 2012). The facility will be located on a 22-acre campus located inside the Free Trade Zone of the Nantong Economic Technology Development Area (NETDA).

The facility will be state of the art and world class with emphasis on total quality and safety at each step of the design process. "This day marks a new chapter for Novast as we are transitioning from commercializing quality prescription products in the United States to focusing on catering the same to the China domestic needs through the collaboration platform with Lilly," said Dr Zhang, president and chief executive of Novast Holdings.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK